<DOC>
	<DOCNO>NCT01894477</DOCNO>
	<brief_summary>This phase II trial study well treosulfan , fludarabine phosphate , total body irradiation donor stem cell transplant work treat patient myelodysplastic syndrome acute myeloid leukemia . Giving chemotherapy , treosulfan fludarabine phosphate , total-body irradiation donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Treosulfan , Fludarabine Phosphate , Total Body Irradiation Before Donor Stem Cell Transplant Treating Patients With Myelodysplastic Syndrome Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine good two treosulfan-based conditioning regimens patient myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( AML ) , compare 6-month progression-free survival . SECONDARY OBJECTIVES : I . Determine effect two condition regimen change gene expression profile , evaluate association gene expression profile disease relapse . II . Determine incidence progression-free survival 1 year 2 year hematopoietic cell transplantation ( HCT ) . III . Evaluate overall survival ( OS ) 6 month , 1 year 2 year HCT . IV . Determine incidence grade II-IV acute graft-versus-host disease ( GVHD ) . V. Determine incidence chronic GVHD . VI . Determine donor chimerism around day +28 +84 . OUTLINE : CONDITIONING REGIMEN : Patients receive treosulfan intravenously ( IV ) 2 hour day -6 -4 fludarabine phosphate IV 30 minute day -6 -2 . Patients undergo low-dose total-body irradiation ( TBI ) day 0 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell ( PBSC ) transplant bone marrow transplant day 0 . GVHD PROPHYLAXIS : Patients related donor receive tacrolimus orally ( PO ) every 8 12 hour day -3 56 taper day 180 . Beginning 4-6 hour PBSC infusion , patient also receive mycophenolate mofetil PO every 12 hour day 28 . Patients unrelated donor receive tacrolimus PO every 8 12 hour day -3 100 taper day 180 . Beginning 4-6 hour PBSC infusion , patient also receive mycophenolate mofetil PO every 8 hour day 40 taper day 96 . NOTE : Patients related donor eligible FHCRC protocol 2545 may receive cyclosporine IV , instead tacrolimus , begin day -3 day 50 taper day 180 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>MDS , myelodysplastic syndrome/myeloproliferative neoplasia overlap disorder ( include chronic myelomonocytic leukemia [ CMML ] , MDS/myeloproliferative neoplasm [ MPN ] unclassifiable syndrome ) AML , acute promyelocytic leukemia ( APL ) , first second remission minimal residual disease With Karnofsky index Lansky PlayPerformance scale &gt; 70 % pretransplant evaluation Able give inform consent ( &gt; 18 year ) , legal guardian capable give informed consent ( &lt; 18 year ) Patients previous autologous allogeneic HCT allow enroll DONOR : Human leukocyte antigen ( HLA ) identical related donor DONOR : Unrelated donor match HLAA , B , C , DRB1 , DQB1 define high resolution deoxyribonucleic acid ( DNA ) typing ; mismatch one HLA allele allow DONOR : Donors able undergo peripheral blood stem cell collection bone marrow harvest DONOR : Donors good general health , Karnofsky Lansky play performance score &gt; 90 % DONOR : Donors able give inform consent ( &gt; 18 year ) , legal guardian capable give informed consent ( &lt; 18 year ) Receiving umbilical cord blood With impaired cardiac function evidence ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) cardiac insufficiency require treatment symptomatic coronary artery disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist With impaired pulmonary function evidence partial pressure oxygen ( pO2 ) &lt; 70 mm Hg carbon monoxide diffuse capability test ( DLCO ) &lt; 70 % predict pO2 &lt; 80 mm Hg DLCO &lt; 60 % predict ; ( , pediatric patient unable perform pulmonary function test , oxygen ( O2 ) saturation &lt; 92 % room air ) , receive supplementary continuous oxygen With impaired renal function evidence creatinineclearance &lt; 50 % age , weight , height serum creatinine &gt; 2 x upper limit normal dialysisdependent With hepatic dysfunction evidence total bilirubin &gt; 2.0 x upper limit normal evidence synthetic dysfunction severe cirrhosis With hepatic dysfunction evidence aspartate aminotransferase ( AST ) &gt; 2.0 x upper limit normal evidence synthetic dysfunction severe cirrhosis With active infectious disease require deferral conditioning , recommend infectious disease specialist With human immunodeficiency virus ( HIV ) positivity active infectious hepatitis With central nervous system ( CNS ) leukemic involvement clear intrathecal chemotherapy , cranial irradiation prior initiate conditioning ( day 6 ) Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy render evidence disease , great 20 % chance disease recurrence within 5 year ; exclusion apply patient nonhematologic malignancy require therapy With life expectancy severely limited disease malignancy Women pregnant lactating With known hypersensitivity treosulfan fludarabine ( fludarabine phosphate ) Receiving another experimental drug within 4 week initiation conditioning ( day 6 ) Unable give inform consent ( &gt; 18 year ) legal guardian ( &lt; 18 year ) unable give inform consent DONOR : Individuals deem unable undergo marrow harvest PBSC mobilization leukapheresis DONOR : Individuals HIVpositive DONOR : Individuals active infectious hepatitis DONOR : Females positive pregnancy test DONOR : Persons unable give inform consent ( &gt; 18 year ) legal guardian ( &lt; 18 year ) unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>